Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
41
QNTM Quote, Financials, Valuation and Earnings
Last price:
$10.02
Seasonality move
:
3.34%
Day range:
$9.51 - $10.19
52-week range:
$2.70 - $38.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.27x
Volume:
34.7K
Avg. volume:
134.3K
1-year change:
139.48%
Market cap:
$38.7M
Revenue:
--
EPS (TTM):
-$13.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QNTM
Quantum BioPharma Ltd.
|
$899.1K | -$2.69 | -- | -35.54% | $17.23 |
|
ACHV
Achieve Life Sciences, Inc.
|
-- | -$0.26 | -- | -22.63% | $15.89 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $10.33 |
|
MDCX
Medicus Pharma Ltd.
|
-- | -$0.38 | -- | -84.42% | $22.03 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -15.25% | $5.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QNTM
Quantum BioPharma Ltd.
|
$10.13 | $17.23 | $38.7M | -- | $0.00 | 0% | -- |
|
ACHV
Achieve Life Sciences, Inc.
|
$4.69 | $15.89 | $249.7M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.68 | $16.67 | $2.1B | 27.95x | $0.00 | 0% | 8.32x |
|
EDSA
Edesa Biotech, Inc.
|
$1.74 | $10.33 | $12.2M | -- | $0.00 | 0% | 31.22x |
|
MDCX
Medicus Pharma Ltd.
|
$2.04 | $22.03 | $44.9M | -- | $0.00 | 0% | -- |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.94 | $5.49 | $100.3M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QNTM
Quantum BioPharma Ltd.
|
-- | 1.527 | -- | -- |
|
ACHV
Achieve Life Sciences, Inc.
|
22.85% | 2.734 | 5.99% | 4.94x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 18.80x |
|
MDCX
Medicus Pharma Ltd.
|
114.82% | -1.403 | 14.49% | 0.81x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QNTM
Quantum BioPharma Ltd.
|
-- | -$4.9M | -- | -- | -- | -$1.9M |
|
ACHV
Achieve Life Sciences, Inc.
|
-$54K | -$14.7M | -139.57% | -189.88% | -- | -$11.3M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.8K | -$1.9M | -80.33% | -80.46% | -- | -$1.8M |
|
MDCX
Medicus Pharma Ltd.
|
-- | -$6.7M | -610.17% | -1316.36% | -- | -$6.8M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
Quantum BioPharma Ltd. vs. Competitors
-
Which has Higher Returns QNTM or ACHV?
Achieve Life Sciences, Inc. has a net margin of -- compared to Quantum BioPharma Ltd.'s net margin of --. Quantum BioPharma Ltd.'s return on equity of -- beat Achieve Life Sciences, Inc.'s return on equity of -189.88%.
Company Gross Margin Earnings Per Share Invested Capital QNTMQuantum BioPharma Ltd.-- -$3.23 -- ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M -
What do Analysts Say About QNTM or ACHV?
Quantum BioPharma Ltd. has a consensus price target of $17.23, signalling upside risk potential of 70.12%. On the other hand Achieve Life Sciences, Inc. has an analysts' consensus of $15.89 which suggests that it could grow by 238.78%. Given that Achieve Life Sciences, Inc. has higher upside potential than Quantum BioPharma Ltd., analysts believe Achieve Life Sciences, Inc. is more attractive than Quantum BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings QNTMQuantum BioPharma Ltd.1 0 0 ACHVAchieve Life Sciences, Inc.6 0 0 -
Is QNTM or ACHV More Risky?
Quantum BioPharma Ltd. has a beta of 0.153, which suggesting that the stock is 84.666% less volatile than S&P 500. In comparison Achieve Life Sciences, Inc. has a beta of 1.690, suggesting its more volatile than the S&P 500 by 68.981%.
-
Which is a Better Dividend Stock QNTM or ACHV?
Quantum BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Achieve Life Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quantum BioPharma Ltd. pays -- of its earnings as a dividend. Achieve Life Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNTM or ACHV?
Quantum BioPharma Ltd. quarterly revenues are --, which are smaller than Achieve Life Sciences, Inc. quarterly revenues of --. Quantum BioPharma Ltd.'s net income of -$9.3M is higher than Achieve Life Sciences, Inc.'s net income of -$14.4M. Notably, Quantum BioPharma Ltd.'s price-to-earnings ratio is -- while Achieve Life Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quantum BioPharma Ltd. is -- versus -- for Achieve Life Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNTMQuantum BioPharma Ltd.-- -- -- -$9.3M ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M
-
Which has Higher Returns QNTM or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Quantum BioPharma Ltd.'s net margin of 42.95%. Quantum BioPharma Ltd.'s return on equity of -- beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital QNTMQuantum BioPharma Ltd.-- -$3.23 -- AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About QNTM or AUPH?
Quantum BioPharma Ltd. has a consensus price target of $17.23, signalling upside risk potential of 70.12%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 6.29%. Given that Quantum BioPharma Ltd. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Quantum BioPharma Ltd. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QNTMQuantum BioPharma Ltd.1 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is QNTM or AUPH More Risky?
Quantum BioPharma Ltd. has a beta of 0.153, which suggesting that the stock is 84.666% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock QNTM or AUPH?
Quantum BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quantum BioPharma Ltd. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNTM or AUPH?
Quantum BioPharma Ltd. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Quantum BioPharma Ltd.'s net income of -$9.3M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Quantum BioPharma Ltd.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quantum BioPharma Ltd. is -- versus 8.32x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNTMQuantum BioPharma Ltd.-- -- -- -$9.3M AUPHAurinia Pharmaceuticals, Inc.8.32x 27.95x $73.5M $31.6M
-
Which has Higher Returns QNTM or EDSA?
Edesa Biotech, Inc. has a net margin of -- compared to Quantum BioPharma Ltd.'s net margin of --. Quantum BioPharma Ltd.'s return on equity of -- beat Edesa Biotech, Inc.'s return on equity of -80.46%.
Company Gross Margin Earnings Per Share Invested Capital QNTMQuantum BioPharma Ltd.-- -$3.23 -- EDSAEdesa Biotech, Inc.-- -$0.25 $14.1M -
What do Analysts Say About QNTM or EDSA?
Quantum BioPharma Ltd. has a consensus price target of $17.23, signalling upside risk potential of 70.12%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 532.18%. Given that Edesa Biotech, Inc. has higher upside potential than Quantum BioPharma Ltd., analysts believe Edesa Biotech, Inc. is more attractive than Quantum BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings QNTMQuantum BioPharma Ltd.1 0 0 EDSAEdesa Biotech, Inc.1 0 0 -
Is QNTM or EDSA More Risky?
Quantum BioPharma Ltd. has a beta of 0.153, which suggesting that the stock is 84.666% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock QNTM or EDSA?
Quantum BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quantum BioPharma Ltd. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNTM or EDSA?
Quantum BioPharma Ltd. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Quantum BioPharma Ltd.'s net income of -$9.3M is lower than Edesa Biotech, Inc.'s net income of -$1.7M. Notably, Quantum BioPharma Ltd.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quantum BioPharma Ltd. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNTMQuantum BioPharma Ltd.-- -- -- -$9.3M EDSAEdesa Biotech, Inc.31.22x -- -- -$1.7M
-
Which has Higher Returns QNTM or MDCX?
Medicus Pharma Ltd. has a net margin of -- compared to Quantum BioPharma Ltd.'s net margin of --. Quantum BioPharma Ltd.'s return on equity of -- beat Medicus Pharma Ltd.'s return on equity of -1316.36%.
Company Gross Margin Earnings Per Share Invested Capital QNTMQuantum BioPharma Ltd.-- -$3.23 -- MDCXMedicus Pharma Ltd.-- -$1.12 $6.2M -
What do Analysts Say About QNTM or MDCX?
Quantum BioPharma Ltd. has a consensus price target of $17.23, signalling upside risk potential of 70.12%. On the other hand Medicus Pharma Ltd. has an analysts' consensus of $22.03 which suggests that it could grow by 980.03%. Given that Medicus Pharma Ltd. has higher upside potential than Quantum BioPharma Ltd., analysts believe Medicus Pharma Ltd. is more attractive than Quantum BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings QNTMQuantum BioPharma Ltd.1 0 0 MDCXMedicus Pharma Ltd.2 0 0 -
Is QNTM or MDCX More Risky?
Quantum BioPharma Ltd. has a beta of 0.153, which suggesting that the stock is 84.666% less volatile than S&P 500. In comparison Medicus Pharma Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QNTM or MDCX?
Quantum BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medicus Pharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quantum BioPharma Ltd. pays -- of its earnings as a dividend. Medicus Pharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNTM or MDCX?
Quantum BioPharma Ltd. quarterly revenues are --, which are smaller than Medicus Pharma Ltd. quarterly revenues of --. Quantum BioPharma Ltd.'s net income of -$9.3M is higher than Medicus Pharma Ltd.'s net income of -$16M. Notably, Quantum BioPharma Ltd.'s price-to-earnings ratio is -- while Medicus Pharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quantum BioPharma Ltd. is -- versus -- for Medicus Pharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNTMQuantum BioPharma Ltd.-- -- -- -$9.3M MDCXMedicus Pharma Ltd.-- -- -- -$16M
-
Which has Higher Returns QNTM or ONCY?
Oncolytics Biotech, Inc. has a net margin of -- compared to Quantum BioPharma Ltd.'s net margin of --. Quantum BioPharma Ltd.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital QNTMQuantum BioPharma Ltd.-- -$3.23 -- ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About QNTM or ONCY?
Quantum BioPharma Ltd. has a consensus price target of $17.23, signalling upside risk potential of 70.12%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 480.67%. Given that Oncolytics Biotech, Inc. has higher upside potential than Quantum BioPharma Ltd., analysts believe Oncolytics Biotech, Inc. is more attractive than Quantum BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings QNTMQuantum BioPharma Ltd.1 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is QNTM or ONCY More Risky?
Quantum BioPharma Ltd. has a beta of 0.153, which suggesting that the stock is 84.666% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock QNTM or ONCY?
Quantum BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quantum BioPharma Ltd. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNTM or ONCY?
Quantum BioPharma Ltd. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Quantum BioPharma Ltd.'s net income of -$9.3M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Quantum BioPharma Ltd.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quantum BioPharma Ltd. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNTMQuantum BioPharma Ltd.-- -- -- -$9.3M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is up 102.52% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
